Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer

被引：0
|
作者：
Maiko Asakuma
Michiko Yamamoto
Mayuko Wada
Shinichiro Ryuge
Ken Katono
Masanori Yokoba
Tomoya Fukui
Akira Takakura
Sakiko Otani
Sachiyo Maki
Satoshi Igawa
Tomoko Yanaihara
Hisashi Mitsufuji
Masaru Kubota
Masato Katagiri
Jiichiro Sasaki
Noriyuki Masuda
机构：
[1] Kitasato University School of Medicine,Department of Respiratory Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
CPT-11; Amrubicin; Small-cell lung cancer; Extensive stage; Phase 1 study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1529 / 1536
页数：7
相关论文
共 50 条
  • [41] Clinical correlation of extensive-stage small-cell lung cancer genomics
    Dowlati, A.
    Lipka, M. B.
    McColl, K.
    Dabir, S.
    Behtaj, M.
    Kresak, A.
    Miron, A.
    Yang, M.
    Sharma, N.
    Fu, P.
    Wildey, G.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 642 - 647
  • [42] Tumor lysis syndrome in extensive-stage small-cell lung cancer
    Beriwal, S
    Singh, S
    Garcia-Young, JA
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 474 - 475
  • [43] Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
    Liu, Chaoyuan
    Zeng, Liang
    Deng, Chao
    Jiang, Wenjuan
    Wang, Yapeng
    Zhou, Yiguang
    Liu, Li
    Wang, Sisi
    Zhou, Chunhua
    Qiu, Zhenhua
    Zeng, Fanxu
    Wu, Fang
    Weng, Jie
    Liu, Xianling
    Yang, Nong
    Ma, Fang
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer
    Crabb, Simon J.
    Bradbury, Jennifer
    Nolan, Luke
    Selman, Diana
    Muthuramalingam, Sethupathi R.
    Cave, Judith
    Johnson, Peter W. M.
    Ottensmeier, Christian
    [J]. CHEMOTHERAPY, 2012, 58 (04) : 257 - 263
  • [45] Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study
    Tibaldi, C
    Prochilo, T
    Russo, F
    Pennucci, MC
    Del Freo, A
    Innocenti, F
    Fabbri, A
    Falcone, A
    Conte, PF
    Baldini, E
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1263 - 1266
  • [46] Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC)
    Langer, C
    Hanna, N
    Einhorn, L
    Sandler, A
    Ansari, R
    Ellis, R
    Byrne, M
    Green, M
    Morrison, M
    Bunn, P
    [J]. LUNG CANCER, 2005, 49 : S53 - S54
  • [47] Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer
    Furuse, K
    Fukuoka, M
    Nishiwaki, Y
    Kurita, Y
    Watanabe, K
    Noda, K
    Ariyoshi, Y
    Tamura, T
    Saijo, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2126 - 2132
  • [48] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    Hanna, N
    Bunn, PA
    Langer, C
    Einhorn, L
    Guthrie, T
    Beck, T
    Ansar, R
    Ellis, P
    Byrne, M
    Morrison, M
    Hariharan, S
    Wang, B
    Sandler, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2038 - 2043
  • [49] A Phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer
    Harada, T.
    Hamada, A.
    Shimokawa, M.
    Takayama, K.
    Kudoh, S.
    Maeno, K.
    Saeki, S.
    Miyawaki, H.
    Moriyama, A.
    Nakagawa, K.
    Nakanishi, Y.
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (02) : 127 - 133
  • [50] Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer
    Fujita, A
    Takabatake, H
    Tagaki, S
    Sekine, K
    [J]. ANTI-CANCER DRUGS, 2000, 11 (10) : 821 - 824
12345